Wellington Management Group LLP Has $205.23 Million Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Wellington Management Group LLP trimmed its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 6.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,376,961 shares of the company’s stock after selling 519,671 shares during the quarter. Wellington Management Group LLP owned approximately 0.09% of Akero Therapeutics worth $205,227,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of AKRO. FMR LLC raised its holdings in shares of Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock valued at $870,000 after buying an additional 26,691 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Akero Therapeutics in the third quarter worth about $1,327,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Akero Therapeutics during the third quarter worth approximately $265,000. Cinctive Capital Management LP bought a new stake in shares of Akero Therapeutics during the third quarter valued at approximately $1,874,000. Finally, Janus Henderson Group PLC increased its holdings in shares of Akero Therapeutics by 2.9% in the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company’s stock valued at $203,053,000 after purchasing an additional 201,225 shares in the last quarter.

Akero Therapeutics Trading Up 8.6 %

NASDAQ:AKRO opened at $41.95 on Thursday. The company has a market cap of $3.34 billion, a P/E ratio of -11.19 and a beta of -0.19. Akero Therapeutics, Inc. has a twelve month low of $17.86 and a twelve month high of $58.40. The business has a 50 day moving average price of $46.92 and a two-hundred day moving average price of $35.38. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on AKRO. HC Wainwright upped their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Monday, March 3rd. Morgan Stanley reiterated an “overweight” rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Canaccord Genuity Group boosted their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, UBS Group increased their price objective on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Akero Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $76.29.

Insider Transactions at Akero Therapeutics

In related news, COO Jonathan Young sold 607 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total transaction of $27,242.16. Following the transaction, the chief operating officer now directly owns 200,540 shares in the company, valued at approximately $9,000,235.20. The trade was a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William Richard White sold 676 shares of the company’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total transaction of $30,338.88. Following the sale, the chief financial officer now directly owns 61,959 shares in the company, valued at $2,780,719.92. This trade represents a 1.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have purchased 341,309 shares of company stock worth $15,863,578 and have sold 242,135 shares worth $12,064,779. Company insiders own 7.94% of the company’s stock.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.